Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers

Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers

Oversubscribed $9M round to underpin rapid platform expansion across drug discovery, AI data generation, and cell therapy manufacturing

Portal surpasses over 100 customers to date, including public highlights by Microsoft, Merck, AbbVie, Mass General Brigham, Ragon Institute, and Purdue University

Expanded on initial $8M DARPA award with Embedded Entrepreneur Initiative (EEI) contract to supercharge commercialization of point-of-care cell therapy manufacturing

Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering and drug discovery platform company, announced updates on significant commercial progress and the closing of an oversubscribed $9M financing round led by NFX and participation from existing investors including IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures.